MOLECULAR IN VITRO DIAGNOSTIC AND SCREENING TESTS FOR ONCOLOGY

92 Pages | 32 Exhibits | 2018 Analysis | Forecasts Through 2022

OVERVIEW:
This analysis includes a discussion of current/forecast markets, products, competitors, and opportunities in the global market for molecular diagnostics for oncology. This report provides five-year market forecasts by segment and region, market drivers, and estimated market share by geographic region.

MOLECULAR DIAGNOSTICS MARKET HIGHLIGHTS

  • The global market for molecular diagnostics for oncology totalled approximately $1.0bn in 2017, with the cervical cancer screening segment accounting for the largest share.
  • The US remains the largest market, accounting for nearly 40% of sales in 2017, although regions outside the US represent good growth potential.
  • Leading competitors in the market include Abbott, Agilent, Hologic, Qiagen, and Roche, among others.
Key Questions Answered
  • What are the key drivers and limiters to this market?
  • Which competitors are leading the market and introducing new technology?
  • How are technological advancements impacting market growth?
  • Which areas of the market are experiencing dynamic growth?
  • How are mergers and acquisitions affecting the market shares of leading competitors?


TABLE OF CONTENTS:
Executive Summary

i. Molecular diagnostics market for oncology 
	a. Selected market drivers and limiters
	b. Market leaders
ii. Methodology 

Exhibit ES-1: Global market for molecular in vitro diagnostic tests for infectious disease, oncology, genetic testing, and blood screening, by segment ($m), 2017 and 2022 
Exhibit ES-2: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), by type of cancer, 2017-22.
Exhibit ES-3: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), by region, 2017-22

1. Market Environment

1.1 Overview of molecular in vitro diagnostics
1.2 Market trends
	1.2.1 Advantages of molecular cancer testing versus immunochemical and biochemical methods
	1.2.2 Companion diagnostics and pharmacogenomics
	1.2.3 Reimbursement 
	1.2.4 Regulatory issues
	1.2.5 Liability issues 
1.3 Target market segments for molecular cancer diagnostics
1.4 Bibliography

Exhibit 1-1: Global market for molecular in vitro diagnostic tests for infectious disease, oncology, genetic testing, and blood screening, by segment ($m), 2017 and 2022 
Exhibit 1-2: Selected molecular in vitro diagnostic tests for oncology, 2018 
Exhibit 1-3: Range of applicability of biochemical assay, immunochemical, and molecular testing in oncology applications
Exhibit 1-4: Selected molecular companion diagnostic tests and associated targeted therapies

2. Cancer Incidence and Prevalence by Type

2.1 Breast cancer
2.2 Prostate cancer
2.3 Lung cancer
2.4 Colorectal cancer
2.5 Melanoma
2.6 Pancreatic cancer
2.7 Hepatocellular cancer
2.8 Cervical cancer
2.9 Oral cancer
2.10 Leukemia and lymphoma 
2.11 Stomach cancer 
2.12 Bibliography

Exhibit 2-1: Cancer incidence by country/region, 2015
Exhibit 2-2: Cancer incidence by country/region, 2020
Exhibit 2-3: Cancer incidence by country/region, 2025
Exhibit 2-4: Cancer incidence forecast, by country/region, 2015-25
Exhibit 2-5: Cancer prevalence, by country/region, 2012

3. Analytical Platforms for Molecular In Vitro Diagnostics for Oncology
 
3.1 Polymerase chain reaction and other nucleic acid amplification technologies
3.2 In situ hybridization
3.3 Immunohistochemistry 
3.4 Next-generation sequencing 
3.5 Microarrays
3.6 Flow cytometry
3.7 Other molecular diagnostic technologies
3.8 Bibliography

Exhibit 3-1: Types of analytical platforms employed in molecular cancer diagnostics, 2018 
Exhibit 3-2: Selected next-generation sequencing technologies, 2018 

4. Molecular In Vitro Diagnostic and Screening Tests for Oncology

4.1 Market drivers and limiters
4.2 End-user characteristics 
4.3 Market for molecular diagnostics, by cancer type and geographic region
	4.3.1 Breast cancer molecular IVD market, by geographic region 
	4.3.2 Prostate cancer molecular diagnostics market, by region
	4.3.3 Lung cancer molecular diagnostics market, by region
	4.3.4 Colorectal cancer molecular diagnostics market, by region
	4.3.5 Melanoma molecular diagnostics market, by region 
	4.3.6 Hepatocellular cancer molecular diagnostics market, by region
	4.3.7 Pancreatic cancer molecular diagnostics market, by region 
	4.3.8 Cervical cancer molecular diagnostics market, by region
	4.3.9 Leukemia and lymphoma molecular diagnostics market, by region 
	4.3.10 Stomach cancer molecular diagnostics market, by region 
	4.3.11 Market for molecular diagnostic products for other cancer types, by region 
4.4 Competitive analysis
	4.4.1 Company sales by cancer type
	4.4.2 Molecular testing laboratory revenues 
4.5 Bibliography

Exhibit 4-1: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), 2017-22 
Exhibit 4-2: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), by region, 2017-22 
Exhibit 4-3: Molecular in vitro diagnostic tests for oncology, global market forecast ($m), by type of cancer, 2017-22
Exhibit 4-4: Molecular in vitro diagnostic tests for breast cancer, global market forecast ($m), by region, 2017-22
Exhibit 4-5: Molecular in vitro diagnostic tests for prostate cancer, global market forecast ($m), by region, 2017-22
Exhibit 4-6: Molecular in vitro diagnostic tests for lung cancer, global market forecast ($m), by region, 2017-22
Exhibit 4-7: Global sales of targeted drugs used in lung cancer therapy ($m), 2015-17
Exhibit 4-8: Molecular in vitro diagnostic tests for colorectal cancer, global market forecast ($m), by region, 2017-22
Exhibit 4-9: Global sales of targeted drugs used in colorectal cancer therapy ($m), 2015-17 
Exhibit 4-10: Molecular in vitro diagnostic tests for melanoma, global market forecast ($m), by region, 2017-22
Exhibit 4-11: Global sales of targeted drugs used in melanoma therapy ($m), 2015-17 
Exhibit 4-12: Molecular in vitro diagnostic tests for cervical cancer, global market forecast ($m), by region, 2017-22
Exhibit 4-13: Prevalence of human papilloma virus infection, by geographic region
Exhibit 4-14: Molecular in vitro diagnostic tests for leukemia/lymphoma, global market forecast ($m), by region, 2017-22
Exhibit 4-15: Molecular in vitro diagnostic tests for other cancer types, global market forecast ($m), by region, 2017-22.
Exhibit 4-16: Molecular in vitro diagnostic tests for oncology, share by supplier ($m), 2017
Exhibit 4-17: Molecular in vitro diagnostic tests for oncology, company sales by cancer type ($m), 2017 
Exhibit 4-18: Molecular oncology in vitro diagnostic testing services market ($m), 2017

APPENDIX: COMPANY LISTING


COMPANIES COVERED:

  1. 23andMe
  2. Abbott Molecular
  3. Admera Health
  4. Agendia
  5. Agilent Technologies
  6. AmoyDx
  7. ARUP Laboratories
  8. AstraZeneca
  9. AutoGenomics
  10. Bayer Pharmaceuticals
  11. BD
  12. BioChain
  13. Biodesix
  14. bioMerieux
  15. Bio-Rad
  16. Bristol-Myers Squibb
  17. Cancer Genetics
  18. Cepheid
  19. Clinical Genomics
  20. Complete Genomics
  21. Danaher
  22. DiaCarta
  23. Epigenomics
  24. Exact Sciences
  25. Fluidigm
  26. Foundation Medicine
  27. GenomeDx
  28. Genomic Expression
  29. Genomic Health
  30. Greiner
  31. Grifols
  32. HTG Molecular Diagnostics
  33. Hologic
  34. Illumina
  35. Invitrogen/Thermo Fisher
  36. Invivoscribe
  37. Iris Molecular Diagnostics/Danaher
  38. Luminex
  39. MDX Health
  40. Merck
  41. MetaMark
  42. MLabs
  43. MolecularMD
  44. Myriad Genetics
  45. NanoString
  46. NantHealth
  47. NeoGenomics
  48. Novartis
  49. Nucleix
  50. Opco
  51. Oxford Nanopore Technologies
  52. Pacific Biosciences
  53. PacificDx
  54. Personalize Dx
  55. Qiagen
  56. Randox
  57. Roche
  58. Savyon Diagnostics
  59. Seegene
  60. Siemens Healthineers
  61. Thermo Fisher Scientific
  62. Two Pore Guys
Contact Us

Need help finding medtech research? Let us help you!